Aug 2026
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
Intacranial TX103 infusion demonstrated acceptable safety and encouraging efficacy in rGBM, supporting a future phase 2 evaluation at the RP2D, and Cerebrospinal fluid showed a marked increase in CAR copy numbers and cytokine release, with minimal peripheral activity and no cumulative toxicity after repeated infusions.
Yang Zhang, Xiaohan Chi, Rui Feng et al.
· Nature Medicine · 2 citations